Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG001 plus platinum chemotherapy with or without bevacizumab versus placebo plus chemotherapy with or without bevacizumab for first-line PD-L1-positive recurrent or metastatic cervical cancer
CTR20230132Phase 3Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of PBI-1308 in Cervical Cancer (CC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Feb 2023; status: active.
02
Drugs
PBI-1308
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20230132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230132.